The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy

Scottish Medical Journal

Volumn 49, Issue 4, 2004, Pages 139-141

  Panthakalam, S ^a   Bhatnagar, D ^a   Klimiuk, P ^a  

^a ROYAL OLDHAM HOSPITAL   (United Kingdom)

Author keywords

Corticosteroid induced diabetes mellitus; Hyperglycaemia; Rheumatoid arthritis (RA)

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; DEFLAZACORT; ETANERCEPT; GLUCOSE; GOLD; INSULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; AWARENESS; CONTROLLED STUDY; CORONARY RISK; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CARE; PATIENT MONITORING; PERIODIC MEDICAL EXAMINATION; PHYSICIAN; PREVALENCE; REVIEW; RHEUMATOID ARTHRITIS;

EID: 11344280116     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1177/003693300404900407     Document Type: Review

References (23)

1. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 1999; 25: 489-505.
2. Van Riel PL, Haagsma CJ, Furst DE. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol. 1999; 13: 689-700
3. Hirsch IB, Paauw DS. Diabetes management in special situations. Endocrinol Metab Clin North Am. 1997; 26: 631-45.
4. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall'omo AM, Imbimbo B. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983; 72: 1814-20.
5. Kahn SE, Horber FF, Prigeon RL, Haymond MW, Porte D Jr. Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. Diabetes. 1993; 42: 1082-5.
6. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N, Uotani S, Matsuo H, Yamaguchi Y, Tokuyama K, Nagataki S. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab. 1996; 81: 2621-6.
7. Owen OE, Cahill GF Jr. Metabolic effects of exogenous glucocorticoids in fasted man. J Clin Invest. 1973; 52: 2596-605.
8. Bruno A, Cavallo-Perin P, Cassader M, Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch Intern Med. 1987; 147: 679-80.
9. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1998; 21(S): 5-19
10. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet. 1999; 354: 617-621
11. DCCT Research Group: The effect of intensive treatment on the development and progression of long-term complications in insulin dependant diabetes mellitus. N Engl J Med 1993; 329: 977-986
12. Venstra D L et al. Incidence and cost of steroid side effects after renal transplantation. Transplantation Proceedings, 1999; 31: 301-02
13. Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergies and corticosteroids for threatened preterm delivery. Obstet Gynecol. 1997; 90: 880-3.
14. Silva F, Queiros J, Vargas G, Henriques A, Sarmento A, Guimaraes S. Risk factors for posttransplant diabetes mellitus and impact of this complication after renal transplantation. Transplant Proc. 2000; 32: 2609-10.
15. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, Fauchald P. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997; 64: 979-83.
16. Ruiz JO, Simmons RL, Calleder CO, Kjellstrand CM, Buselmeier TJ, Najarian JS. Steroid diabetes in renal transplant recipients: pathogenetic factors and prognosis. Surgery. 1973; 73: 759-65.
17. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983; 6: 23-5.
18. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997 111: 732-743
19. Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol. 1972; 49: 329-36.
20. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994; 236: 619-32.
21. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucooorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994; 154: 97-101.
22. Fujibayashi K, Nagasaka S, Itabashi N, Kawakami A, Nakamura T, Kusaka I, Ishikawa S, Saito T. Troglitazone efficacy in a subject with glucocorticoid-induce diabetes. Diabetes Care. 1999;22:2088-9
23. Roach P, Yue L, Arora V. Improved Postprandial Glycemic Control During Treatment With Humalog Mix25, a Novel Protamine-Based Insulin Lispro Formulation. Diabetes Care 1999;22:1258-1261